1. Home
  2. IART vs TYRA Comparison

IART vs TYRA Comparison

Compare IART & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Integra LifeSciences Holdings Corporation

IART

Integra LifeSciences Holdings Corporation

N/A

Current Price

$13.08

Market Cap

1.2B

Sector

Health Care

ML Signal

N/A

Logo Tyra Biosciences Inc.

TYRA

Tyra Biosciences Inc.

N/A

Current Price

$22.59

Market Cap

1.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
IART
TYRA
Founded
1989
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.2B
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
IART
TYRA
Price
$13.08
$22.59
Analyst Decision
Hold
Strong Buy
Analyst Count
7
6
Target Price
$15.00
$32.17
AVG Volume (30 Days)
837.4K
576.3K
Earning Date
10-30-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,642,966,000.00
N/A
Revenue This Year
$3.26
N/A
Revenue Next Year
$2.71
N/A
P/E Ratio
N/A
N/A
Revenue Growth
4.99
N/A
52 Week Low
$10.87
$6.42
52 Week High
$27.13
$24.05

Technical Indicators

Market Signals
Indicator
IART
TYRA
Relative Strength Index (RSI) 49.22 64.23
Support Level $13.27 $21.65
Resistance Level $14.35 $23.74
Average True Range (ATR) 0.57 1.31
MACD 0.03 -0.15
Stochastic Oscillator 18.52 61.51

Price Performance

Historical Comparison
IART
TYRA

About IART Integra LifeSciences Holdings Corporation

Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

Share on Social Networks: